Market revenue in 2023 | USD 24,496.5 million |
Market revenue in 2030 | USD 39,069.3 million |
Growth rate | 6.9% (CAGR from 2023 to 2030) |
Largest segment | Liquid delivery device |
Fastest growing segment | Liquid Delivery Device |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Powder delivery device, Liquid Delivery Device, Pressurized Metered Dose Inhaler |
Key market players worldwide | GSK PLC ADR, Teva Pharmaceutical Industries Ltd, AptarGroup Inc, UCB SA, Teleflex Inc, 3M Co, OptiNose Inc, Bespak, Intersect ENT |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intranasal drug and vaccine delivery market will help companies and investors design strategic landscapes.
Liquid delivery device was the largest segment with a revenue share of 43.36% in 2023. Horizon Databook has segmented the U.S. intranasal drug and vaccine delivery market based on powder delivery device, liquid delivery device, pressurized metered dose inhaler covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. accounted for the largest market in the North America intranasal drug and vaccine delivery market. The U.S. dominated the overall North American market in terms of revenue share in 2021 with 83.2% share.
The country’s well-established healthcare infrastructure and favorable government policies ensure availability of advanced healthcare services. Increasing incidence of chronic diseases such as sinusitis and rhinitis is expected to drive the market during the forecast period. Number of adults with diagnosed sinusitis is 28.9 million.
Increasing incidence of chronic diseases such as sinusitis and rhinitis is expected to drive the market during the forecast period. According to the CDC, around 28.9 million of adults were diagnosed with sinusitis in the U.S. in 2018.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. intranasal drug and vaccine delivery market , including forecasts for subscribers. This country databook contains high-level insights into U.S. intranasal drug and vaccine delivery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account